Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07807865 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)

Name: A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD) — clinical trial record (NCT07807865)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorIntra-Cellular Therapies, Inc.

Started2026-09-03

View on ClinicalTrials.gov ↗

Intra-Cellular Therapies, Inc.

18 trials monitored

See 3 trials at risk

Anxiety

2,229 trials monitored

See 91 trials at risk

The purpose of this study is to assess how safe ITI-1284 is and how well it can be tolerated in long-term, when given alone or with other medicines, in participants with generalized anxiety disorder (GAD) who have not responded to treatment previously. GAD is a mental health condition defined by constant, uncontrollable worry about everyday things that lasts for six months or more.

Trial Details

NCT Number	NCT07807865
Lead Sponsor	Intra-Cellular Therapies, Inc.
Conditions	Generalized Anxiety Disorder
Enrollment	900 participants
Start Date	2026-09-03
Primary Completion	2030-02-18 (estimated)
Study Completion	2030-03-04 (estimated)
Updated on ClinicalTrials.gov	2026-09-29